0.0115803814713896 0.00749318801089926 0.00681198910081754 0.00885558583106272 -0.0326975476839236 0.0204223433242508 -0.0640326975476839 -0.0803814713896458
Sign Up Today X
Thanks for submitting the form.
Stockreport

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

NovoCure Limited - Ordinary Shares (NVCR)  More Company Research Source: Business Wire
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 millionOptune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).“In 2025, a record number of patients received treatment with Novocure’s Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology,” said Frank Leonard, CEO, Novocure. “This momentum continues in 2026 with the U.S. FDA approval of Optune Pax for pancreatic cancer, an achievement we are incredibly proud of given the exceptional challenge of developin [Read more]
IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
NVCR alerts
from News Quantified
NVCR
NEWS
NVCR
Earnings
NVCR
Analyst Actions
NVCR
SEC Filings
Stockreport

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

NovoCure Limited - Ordinary Shares  (NVCR) 
More Company Research Source: Business Wire
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 millionOptune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).“In 2025, a record number of patients received treatment with Novocure’s Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology,” said Frank Leonard, CEO, Novocure. “This momentum continues in 2026 with the U.S. FDA approval of Optune Pax for pancreatic cancer, an achievement we are incredibly proud of given the exceptional challenge of developin [Read more]
IMPACT SNAPSHOT
EVENT TIME:
NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS